Advanced drug delivery systems market seen reaching $433.56 billion by 2030

The advanced drug delivery systems market is projected to rise from $285.59 billion in 2025 to $433.56 billion by 2030, driven by chronic disease prevalence, biologic drugs and personalized medicine. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Advanced drug delivery systems are becoming more important as drug makers look to improve treatment precision, reduce side effects and boost patient outcomes. - The market’s projected growth points to rising demand for targeted, controlled and patient-friendly therapies across chronic and complex conditions.

What happened: - The Business Research Company released a 2026 market report on advanced drug delivery systems on July 23, 2026. - The report values the market at $285.59 billion in 2025 and projects $310.15 billion in 2026. - The report forecasts the market will reach $433.56 billion by 2030. - The report says the market will grow at an 8.7% CAGR through the forecast period. - Download a free sample of the report - View the full advanced drug delivery systems market report

The details: - Advanced drug delivery systems are designed to improve the precision and effectiveness of pharmaceutical treatments. - The systems aim to deliver drugs at optimal dosages, target specific tissues and release medications at controlled rates. - The technology is intended to improve bioavailability and help medications act where they are needed most. - The report links market growth to pharmaceutical R&D expansion, rising chronic disease cases, formulation science advances, higher use of injectable drugs and a stronger focus on treatment outcomes. - The report says future growth will also be supported by personalized medicine, broader biologic drug use, nanotechnology-based therapies, efforts to reduce drug-related side effects and higher investment in advanced delivery platforms. - The report highlights growing adoption of targeted delivery methods, greater use of nanocarrier formulations, more interest in controlled-release systems, growth in biologic and biosimilar therapies and a stronger focus on patient-friendly administration. - The report says chronic diseases are a major catalyst because they often require ongoing care and are influenced by tobacco use, poor diet, inactivity and excessive alcohol consumption. - In May 2023, the United Nations reported chronic diseases caused seven out of 10 deaths in the United States and more than 1.7 million deaths annually.

Between the lines: - The forecast suggests drug delivery is shifting from a supporting function to a core part of treatment design, especially for biologics and therapies that need greater precision. - North America’s lead reflects established pharmaceutical infrastructure and healthcare spending, while Asia-Pacific’s growth outlook suggests faster adoption in expanding healthcare markets. - The report’s emphasis on nanocarriers and controlled release points to a market where technical differentiation may matter as much as drug chemistry.

What's next: - The report expects continued momentum through 2030 as drug makers increase investment in delivery technologies that improve convenience, targeting and outcomes. - The company says its 2026 reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report covers regional opportunities across North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The bottom line: - Advanced drug delivery systems are moving into a high-growth phase, with chronic disease demand and next-generation biologics keeping the market on a steep upward path.